126 related articles for article (PubMed ID: 37154765)
1.
Zechner M; Castro Jaramillo CA; Zubler NS; Taddio MF; Mu L; Altmann KH; Krämer SD
J Med Chem; 2023 May; 66(10):6782-6797. PubMed ID: 37154765
[TBL] [Abstract][Full Text] [Related]
2. Influence of breast cancer resistance protein and P-glycoprotein on tissue distribution and excretion of Ko143 assessed with PET imaging in mice.
Mairinger S; Zoufal V; Wanek T; Traxl A; Filip T; Sauberer M; Stanek J; Kuntner C; Pahnke J; Müller M; Langer O
Eur J Pharm Sci; 2018 Mar; 115():212-222. PubMed ID: 29360507
[TBL] [Abstract][Full Text] [Related]
3. Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C.
Allen JD; van Loevezijn A; Lakhai JM; van der Valk M; van Tellingen O; Reid G; Schellens JH; Koomen GJ; Schinkel AH
Mol Cancer Ther; 2002 Apr; 1(6):417-25. PubMed ID: 12477054
[TBL] [Abstract][Full Text] [Related]
4. Breast Cancer Resistance Protein and P-Glycoprotein Influence In Vivo Disposition of 11C-Erlotinib.
Traxl A; Wanek T; Mairinger S; Stanek J; Filip T; Sauberer M; Müller M; Kuntner C; Langer O
J Nucl Med; 2015 Dec; 56(12):1930-6. PubMed ID: 26359257
[TBL] [Abstract][Full Text] [Related]
5. Breast cancer resistance protein (BCRP/ABCG2) and P-glycoprotein (P-GP/ABCB1) restrict oral availability and brain accumulation of the PARP inhibitor rucaparib (AG-014699).
Durmus S; Sparidans RW; van Esch A; Wagenaar E; Beijnen JH; Schinkel AH
Pharm Res; 2015 Jan; 32(1):37-46. PubMed ID: 24962512
[TBL] [Abstract][Full Text] [Related]
6. Measurement of Hepatic ABCB1 and ABCG2 Transport Activity with [
Hernández Lozano I; Bauer M; Wulkersdorfer B; Traxl A; Philippe C; Weber M; Häusler S; Stieger B; Jäger W; Mairinger S; Wanek T; Hacker M; Zeitlinger M; Langer O
Mol Pharm; 2020 Jan; 17(1):316-326. PubMed ID: 31790256
[TBL] [Abstract][Full Text] [Related]
7. Impact of P-gp and BCRP on pulmonary drug disposition assessed by PET imaging in rats.
Mairinger S; Hernández-Lozano I; Filip T; Sauberer M; Löbsch M; Stanek J; Wanek T; Sake JA; Pekar T; Ehrhardt C; Langer O
J Control Release; 2022 Sep; 349():109-117. PubMed ID: 35798092
[TBL] [Abstract][Full Text] [Related]
8. Brain and Testis Accumulation of Regorafenib is Restricted by Breast Cancer Resistance Protein (BCRP/ABCG2) and P-glycoprotein (P-GP/ABCB1).
Kort A; Durmus S; Sparidans RW; Wagenaar E; Beijnen JH; Schinkel AH
Pharm Res; 2015 Jul; 32(7):2205-16. PubMed ID: 25563977
[TBL] [Abstract][Full Text] [Related]
9. Brain accumulation of the EML4-ALK inhibitor ceritinib is restricted by P-glycoprotein (P-GP/ABCB1) and breast cancer resistance protein (BCRP/ABCG2).
Kort A; Sparidans RW; Wagenaar E; Beijnen JH; Schinkel AH
Pharmacol Res; 2015 Dec; 102():200-7. PubMed ID: 26361725
[TBL] [Abstract][Full Text] [Related]
10. The gut microbiota ellagic acid-derived metabolite urolithin A and its sulfate conjugate are substrates for the drug efflux transporter breast cancer resistance protein (ABCG2/BCRP).
González-Sarrías A; Miguel V; Merino G; Lucas R; Morales JC; Tomás-Barberán F; Alvarez AI; Espín JC
J Agric Food Chem; 2013 May; 61(18):4352-9. PubMed ID: 23586460
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of ABCB1 and ABCG2 at the Mouse Blood-Brain Barrier with Marketed Drugs To Improve Brain Delivery of the Model ABCB1/ABCG2 Substrate [
Traxl A; Mairinger S; Filip T; Sauberer M; Stanek J; Poschner S; Jäger W; Zoufal V; Novarino G; Tournier N; Bauer M; Wanek T; Langer O
Mol Pharm; 2019 Mar; 16(3):1282-1293. PubMed ID: 30694684
[TBL] [Abstract][Full Text] [Related]
12. The role of drug efflux and uptake transporters ABCB1 (P-gp), ABCG2 (BCRP) and OATP1A/1B and of CYP3A4 in the pharmacokinetics of the CDK inhibitor milciclib.
Martínez-Chávez A; Broeders J; Lebre MC; Tibben MT; Rosing H; Beijnen JH; Schinkel AH
Eur J Pharm Sci; 2021 Apr; 159():105740. PubMed ID: 33524505
[TBL] [Abstract][Full Text] [Related]
13. The "specific" P-glycoprotein inhibitor Tariquidar is also a substrate and an inhibitor for breast cancer resistance protein (BCRP/ABCG2).
Kannan P; Telu S; Shukla S; Ambudkar SV; Pike VW; Halldin C; Gottesman MM; Innis RB; Hall MD
ACS Chem Neurosci; 2011 Feb; 2(2):82-9. PubMed ID: 22778859
[TBL] [Abstract][Full Text] [Related]
14. PET-CT imaging with [(18)F]-gefitinib to measure Abcb1a/1b (P-gp) and Abcg2 (Bcrp1) mediated drug-drug interactions at the murine blood-brain barrier.
Vlaming ML; Läppchen T; Jansen HT; Kivits S; van Driel A; van de Steeg E; van der Hoorn JW; Sio CF; Steinbach OC; DeGroot J
Nucl Med Biol; 2015 Nov; 42(11):833-41. PubMed ID: 26264927
[TBL] [Abstract][Full Text] [Related]
15. The antiepileptic drug lamotrigine is a substrate of mouse and human breast cancer resistance protein (ABCG2).
Römermann K; Helmer R; Löscher W
Neuropharmacology; 2015 Jun; 93():7-14. PubMed ID: 25645391
[TBL] [Abstract][Full Text] [Related]
16. P-glycoprotein and breast cancer resistance protein restrict brigatinib brain accumulation and toxicity, and, alongside CYP3A, limit its oral availability.
Li W; Sparidans RW; Wang Y; Lebre MC; Beijnen JH; Schinkel AH
Pharmacol Res; 2018 Nov; 137():47-55. PubMed ID: 30253203
[TBL] [Abstract][Full Text] [Related]
17. Reversal effect of FW-04-806, a macrolide dilactone compound, on multidrug resistance mediated by ABCB1 and ABCG2 in vitro and in vivo.
Zhang Z; Ma C; Li P; Wu M; Ye S; Fu L; Xu J
Cell Commun Signal; 2019 Sep; 17(1):110. PubMed ID: 31472682
[TBL] [Abstract][Full Text] [Related]
18. P-glycoprotein (MDR1/ABCB1) and Breast Cancer Resistance Protein (BCRP/ABCG2) limit brain accumulation of the FLT3 inhibitor quizartinib in mice.
Wang J; Gan C; Retmana IA; Sparidans RW; Li W; Lebre MC; Beijnen JH; Schinkel AH
Int J Pharm; 2019 Feb; 556():172-180. PubMed ID: 30553002
[TBL] [Abstract][Full Text] [Related]
19. A novel PET protocol for visualization of breast cancer resistance protein function at the blood-brain barrier.
Wanek T; Kuntner C; Bankstahl JP; Mairinger S; Bankstahl M; Stanek J; Sauberer M; Filip T; Erker T; Müller M; Löscher W; Langer O
J Cereb Blood Flow Metab; 2012 Nov; 32(11):2002-11. PubMed ID: 22828996
[TBL] [Abstract][Full Text] [Related]
20. Brain Distribution of Dual ABCB1/ABCG2 Substrates Is Unaltered in a Beta-Amyloidosis Mouse Model.
Wanek T; Zoufal V; Brackhan M; Krohn M; Mairinger S; Filip T; Sauberer M; Stanek J; Pekar T; Pahnke J; Langer O
Int J Mol Sci; 2020 Nov; 21(21):. PubMed ID: 33153231
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
